GSK Urges Court to Dismiss Moderna’s Counterclaims in mRNA Patent Dispute

GlaxoSmithKline (GSK) is seeking a swift dismissal of some counterclaims presented by Moderna in an ongoing patent dispute concerning mRNA vaccine technology, as filed in a Delaware federal court. This legal confrontation underscores the complex web of patent rights entangling these pharmaceutical giants in the aftermath of expedited vaccine development efforts. Further details of GSK’s legal maneuvers and Moderna’s counter-position can be found in this Law360 article.